Pelthos Therapeutics (PTHS) EBT Margin (2025 - 2026)
Pelthos Therapeutics (PTHS) posted EBT Margin of 182.92% for Q2 2026, up 20.44% on a QoQ basis from 229.9% in Q1 2026.
Powered by 
Analysis
Pelthos Therapeutics (PTHS) EBT Margin (2025 - 2026) Analysis & Trends
Pelthos Therapeutics has reported EBT Margin for 2 years, with the latest figure at 182.92% in Q2 2026.
- On a quarterly basis, EBT Margin changed N/A year-over-year to 182.92% in Q2 2026; TTM through Jun 2026 was 220.44%, a N/A change from a year earlier, with the FY2025 full-year figure at 301.91%, changed N/A from the prior year.
- EBT Margin was 182.92% for Q2 2026 at Pelthos Therapeutics, up from 229.9% in the prior quarter.
- The five-year high for EBT Margin was 182.92% in Q2 2026, with the low at 314.34% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.22 Bn | 620.47 Bn | 17.26 Bn | 26.66% |
| 2 | AbbVie | 446.22 Bn | 439.65 Bn | 12.70 Bn | 25.18% |
| 3 | Merck | 357.04 Bn | 349.90 Bn | 12.21 Bn | -4.11% |
| 4 | Novartis Ag | 268.38 Bn | 260.69 Bn | 11.24 Bn | 29.63% |
| 5 | Pfizer | 156.32 Bn | 144.62 Bn | 10.94 Bn | -4.34% |
| 6 | Sanofi | 52.23 Bn | 44.85 Bn | 10.79 Bn | 12.17% |
| 7 | Revolution Medicines | 43.18 Bn | 43.18 Bn | - | - |
| 8 | Incyte | 24.85 Bn | 20.31 Bn | 1.57 Bn | 44.89% |
| 9 | United Therapeutics | 21.29 Bn | 18.62 Bn | 683.80 Mn | 47.58% |
| 10 | Pelthos Therapeutics | 80.38 Mn | 55.82 Mn | 21.23 Mn | -182.92% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -182.92% |
| Mar 31, 2026 | -229.90% |
| Dec 31, 2025 | -314.34% |
| Sep 30, 2025 | -225.53% |